Active toxoplasma chorioretinitis in immunocompromised patients: a case series
Abstract
##plugins.themes.bootstrap3.article.details##
Anti-toxoplasmic therapy, immunosuppression, ocular toxoplasmosis, toxoplasma chorioretinitis, uveitis
2. Javadzadeh S, Gkini MA, Panos GD, Adewoyin T, Bewley A. Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis. Clin Exp Dermatol. 2020 Aug;45(6):802-804. doi: 10.1111/ced.14198. Epub 2020 Mar 25. PMID: 32212270.
3. Rodrigues KF, Faria e Arantes TE, Muccioli C, Neto JL, Pinheiro MM. Incidence of Toxoplasma retinochoroiditis in patients with ankylosing spondylitis after using TNF-α blockers. Parasitol Int. 2013 Jun;62(3):272-5. doi: 10.1016/j.parint.2013.02.003. PMID: 23485566.
4. Standardization of Uveitis Nomenclature (SUN) Working Group. Classification Criteria for Toxoplasmic Retinitis. Am J Ophthalmol. 2021 Aug;228:134-141. doi: 10.1016/j.ajo.2021.03.042. PMID: 33845002; PMCID: PMC8594742.
5. Xu K, Hao Y. Determination of the density of human nuclear cataract lenses. Mol Med Rep. 2013 Nov;8(5):1300-4. doi: 10.3892/mmr.2013.1673. PMID: 24026512; PMCID: PMC3820609.
6. Davis JL, Madow B, Cornett J, et al. Scale for photographic grading of vitreous haze in uveitis. Am J Ophthalmol. 2010 Nov;150(5):637-641.e1. doi: 10.1016/j.ajo.2010.05.036. PMID: 20719302; PMCID: PMC3220938.
7. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16. doi: 10.1016/j.ajo.2005.03.057. PMID: 16196117; PMCID: PMC8935739.
8. Smith JR, Cunningham ET Jr. Atypical presentations of ocular toxoplasmosis. Curr Opin Ophthalmol. 2002 Dec;13(6):387-92. doi: 10.1097/00055735-200212000-00008. PMID: 12441842.
9. Fardeau C, Romand S, Rao NA, et al. Diagnosis of toxoplasmic retinochoroiditis with atypical clinical features. Am J Ophthalmol. 2002 Aug;134(2):196-203. doi: 10.1016/s0002-9394(02)01500-3. PMID: 12140026.
10. Figueroa-Vercellino JP, Miguel L, Moll-Udina A, et al. Atypical toxoplasmic retinochoroiditis in patients with malignant hematological diseases. Arch Soc Esp Oftalmol (Engl Ed). 2021 Mar;96(3):152-156. English, Spanish. doi: 10.1016/j.oftal.2020.05.032. PMID: 32651033.
11. Theodoropoulou S, Schmoll C, Templeton K, Dhillon B. Atypical toxoplasmic retinochoroiditis. BMJ Case Rep. 2012 May 30;2012:bcr1220115419. doi: 10.1136/bcr.12.2011.5419. PMID: 22669878; PMCID: PMC4543018.
12. Lassoued S, Zabraniecki L, Marin F, Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2007 Feb;36(4):262-3. doi: 10.1016/j.semarthrit.2006.08.004. PMID: 17067660.
13. Holland GN, Engstrom RE Jr, Glasgow BJ, et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1988 Dec 15;106(6):653-67. doi: 10.1016/0002-9394(88)90697-6. PMID: 3195645.
14. Elkins BS, Holland GN, Opremcak EM, et al. Ocular toxoplasmosis misdiagnosed as cytomegalovirus retinopathy in immunocompromised patients. Ophthalmology. 1994 Mar;101(3):499-507. doi: 10.1016/s0161-6420(13)31267-6. PMID: 8127570.
15. Conrath J, Mouly-Bandini A, Collart F, Ridings B. Toxoplasma gondii retinochoroiditis after cardiac transplantation. Graefes Arch Clin Exp Ophthalmol. 2003 Apr;241(4):334-8. doi: 10.1007/s00417-003-0647-3. PMID: 12719997.
16. Garg A, McKay BR, Francisconi CLM, Muni RH. Toxoplasmosis chorioretinitis mimicking cytomegalovirus retinitis in an immunocompromised pediatric patient following bone marrow transplantation. GMS Ophthalmol Cases. 2022 Jun 7;12:Doc14. doi: 10.3205/oc000201. PMID: 35912126; PMCID: PMC9284721.
17. Galván Ramírez ML, Castillo-de-León Y, Espinoza-Oliva M, et al. Acute infection of Toxoplasma gondii and cytomegalovirus reactivation in a pediatric patient receiving liver transplant. Transpl Infect Dis. 2006 Dec;8(4):233-6. doi: 10.1111/j.1399-3062.2006.00140.x. PMID: 17116139.
18. Walkden A, Wig S, Bhatt PR, Jones NP, Steeples LR. Atypical Ocular Toxoplasmosis During Adalimumab Anti-Tumor Necrosis Factor Therapy for Rheumatoid Arthritis. J Clin Rheumatol. 2020 Dec;26(8):e279-e280. doi: 10.1097/RHU.0000000000001124. PMID: 31295158.
19. Crosson JN, Kuthyar S, Shantha JG, et al. Toxoplasmosis chorioretinitis mimicking acute retinal necrosis associated with local corticosteroid. Int J Retina Vitreous. 2020 Jun 3;6:21. doi: 10.1186/s40942-020-00225-0. PMID: 32514378; PMCID: PMC7268411.
20. Oray M, Ozdal PC, Cebeci Z, Kir N, Tugal-Tutkun I. Fulminant Ocular Toxoplasmosis: The Hazards of Corticosteroid Monotherapy. Ocul Immunol Inflamm. 2016 Dec;24(6):637-646. doi: 10.3109/09273948.2015.1057599. PMID: 26647176.
21. Wong R, dell'Omo R, Marino M, et al. Toxoplasma gondii: an atypical presentation of toxoplasma as optic disc swelling and hemispherical retinal vein occlusion treated with intravitreal clindamycin. Int Ophthalmol. 2009 Jun;29(3):195-8. doi: 10.1007/s10792-008-9192-8. PMID: 18297246.
22. Kim SJ, Scott IU, Brown GC, et al. Interventions for toxoplasma retinochoroiditis: a report by the American Academy of Ophthalmology. Ophthalmology. 2013 Feb;120(2):371-8. doi: 10.1016/j.ophtha.2012.07.061. PMID: 23062648.
23. Kishore K, Conway MD, Peyman GA. Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. Ophthalmic Surg Lasers. 2001 May-Jun;32(3):183-92. PMID: 11371084.
24. Hedayatfar A, Zand A, Faghihi H, Gordiz A, Abdi F. Macular Infarction following Intravitreal Clindamycin Injection : A Case Report. J Curr Ophthalmol. 2021 Oct 22;33(3):349-353. doi: 10.4103/joco.joco_150_20. PMID: 34765827; PMCID: PMC8579790.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.